Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands

Objective: Chemotherapy in the last month of life for patients with metastatic lung cancer is often considered as aggressive end-of-life care. Targeted therapy with Tyrosine Kinase Inhibitors (TKIs) is a relatively new treatment of which not much is known yet about use in the last month of life. We examined what percentage of patients received chemotherapy or TKIs in the last month of life in the Netherlands. Methods: Patient files were drawn from 10 hospitals across the Netherlands. Patients had to meet the following eligibility criteria: metastatic lung cancer; died between June 1, 2013 and... Mehr ...

Verfasser: Mieras, A. (Adinda)
Becker-Commissaris, A. (Annemarie)
Pasman, H.R.W. (H. Roeline W.)
Dingemans, A.-M.M.C. (Anne-Marie M. C.)
Kok, E.V. (Edith V.)
Cornelissen, R. (Robin)
Jacobs, W. (Wouter)
van den Berg, J.W. (Jan Willem)
Welling, A.
Bogaarts, B.A.H.A. (Brigitte A. H. A.)
Pronk, L. (Lemke)
Onwuteaka-Philipsen, B.D. (Bregje)
Dokumenttyp: Artikel
Erscheinungsdatum: 2019
Schlagwörter: aggressive care / cancer treatment / chemotherapy / end of life / metastatic lung cancer / Tyrosine Kinase Inhibitors
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29615581
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://repub.eur.nl/pub/122956